Scilex Holding Co (SCLX) Stock Analysis
Scilex Holding Co
▾ What's in the 50/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.
How to read SCLX (pre-profit growth)
This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.
-
1
Reverse-DCF — the growth the price demands ↓
It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
-
2
Cash runway ↓
Can it reach profitability before it has to raise money and dilute shareholders?
-
3
Interactive calculator ↓
Set your own growth + margin assumptions and see what the business would be worth if you are right.
Standard DCF doesn't fit SCLX well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value biotechnology. Reverse DCF + Football Field also work as cross-checks.
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✗ Positive net incomeNet income -$374.1M in FY2025.Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
-
✓ Positive operating cash flowOperating cash flow $3.8M (was $19.3M the prior year).
-
✓ Cash flow backs up reported profitOperating cash flow $3.8M vs net income -$374.1M.
-
✗ Return on assets improvingReturn on assets -102.5% vs -78.3% a year ago.Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
-
✓ Debt load (vs assets)Total debt is 22.8% of assets vs 37.5% a year ago ($83.3M of $365.0M assets).
-
✗ Short-term liquidity (current ratio)Current ratio 0.08x vs 0.16x a year ago — below 1.0, a caution flag.Why this matters: The current ratio compares assets it can turn to cash within a year against bills due within a year. Below 1.0 means it may struggle to cover near-term obligations.
-
✗ Share count (dilution)Share count rose 8.8% (0.0M → 0.0M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
✓ Pricing power (gross margin)Gross margin 415.8% vs 295.8% a year ago.
-
✗ Sales per asset (asset turnover)Asset turnover 0.08x vs 0.61x a year ago.Why this matters: Asset turnover measures how much revenue each dollar of assets generates. Rising = more productive use of the asset base.
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
A standard discounted cash flowDCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation → (DCF) valuation is not meaningful for Scilex Holding Co. because its net income has been negative in 5 out of the last 5 years, indicating a lack of consistent profitability. Investors are likely betting on the potential success of its drug pipeline and future market penetration, which are not captured in backward-looking cash flow models. The market may be assigning value to potential regulatory approvals and commercialization milestones for its pain management products, which are not in the model. The number one quantifiable risk is the current ratio of 0.08, indicating significant short-term liquidity challenges.
As of 3 months ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
- Announcement of new regulatory approvals for pipeline drugs
- Quarterly revenue growth rates for commercialized products
- Updates on cash runway and financing activities
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Gross margin improved to 416% (+120 pts).
- Revenue fell -47% to $30.3M.
- Free cash flow is negative at -$11.8M — the cash burn widened vs last year.
- Still unprofitable at -$374.1M — loss widening.
Management & Leadership
J. Patrick Butrus serves as the Chief Executive Officer and Chairman of Scilex Holding Company. He has been instrumental in guiding the company's strategic direction in the pain management sector. Dr. D. Lynn Kirkpatrick is the President and Chief Scientific Officer, overseeing research and development.
What They Make
Scilex Holding Co. is a pharmaceutical company focused on developing and commercializing non-opioid pain management products. Its primary customers are healthcare providers and patients seeking alternative pain relief solutions.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.
The market is pricing SCLX based on expectations for future revenue growth and the success of its product pipeline, rather than current cash flow, as evidenced by negative net income in 5 out of 5 years. The market may be assigning value to the potential for new drug approvals and the expansion of its commercialized products into broader markets, which are not in the model. Investors are likely focused on the company's ability to fund its operations and advance its drug candidates, given its rising long-term debt and low current ratio.
Business Model & Valuation
How They Make Money
The company funds its operations primarily through equity raises and debt, as indicated by rising long-term debt and negative net income, with no dividends or buybacks.
Growth / Revenue DCF
Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.
Show advanced inputs
| Revenue Growth | 2.0% |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project product, services and recurring/cloud lines independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Revenue has been roughly flat, declining -0.9% per year over the last four years, from $31M to $30M.
Geography & Markets
Scilex Holding Co. is headquartered in the US and primarily operates within the North American pharmaceutical market. Specific geographic revenue mix is not available from current data sources.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)63.8NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (7 notes — click to expand/collapse)
Guardrail Notes (5)
- FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
- Terminal growth (3%) capped to 1.6% (80% of near-term growth 2%).
- Illiquidity discount 15% applied (small/micro-cap — harder to exit, demand a margin).
- Extreme valuation (P/IV withheld — see the note above); output dominated by data/units issue (often a multi-class share-count mismatch). Suppressed.
- DATA UNAVAILABLE: per-share values suppressed due to missing/unreliable shares data.
FINANCIALS
Financial Statements (5-year tables — click to expand)
From Scilex Holding Co's SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | 30.3M | -374.1M | $-36.48 |
| 2024 | 56.6M | -72.8M | $-8.05 |
| 2023 | 46.7M | -114.3M | $-1.28 |
| 2022 | 38.0M | -23.4M | $-0.17 |
| 2021 | 31.3M | -88.4M | $-0.67 |
Cash Flow (5yr)
| Year | Operating CF | CapEx | − SBC & adj. | Free Cash Flow |
|---|---|---|---|---|
| 2025 | 3.8M | 133,000 | 15.5M | -11.8M |
| 2024 | 19.3M | — | 15.7M | 3.7M |
| 2023 | -20.7M | 30,000 | 14.6M | -35.3M |
| 2022 | -21.3M | 7,000 | 5.3M | -26.5M |
| 2021 | -28.7M | — | 5.8M | -34.5M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: 3.8M − 133,000 − 15.5M (SBC & adj.) = -11.8M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.
Balance Sheet
| Total Assets | 365.0M |
| Total Liabilities | 576.7M |
| Equity | -207.8M |
| Total Debt | 83.3M |
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.